Annual CFI
-$336.35 M
-$505.70 M-298.61%
31 December 2023
Summary:
Alnylam Pharmaceuticals annual cash flow from investing activities is currently -$336.35 million, with the most recent change of -$505.70 million (-298.61%) on 31 December 2023. During the last 3 years, it has risen by +$99.17 million (+22.77%). ALNY annual CFI is now -223.23% below its all-time high of $272.94 million, reached on 31 December 2018.ALNY Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFI
-$30.25 M
-$64.19 M-189.13%
30 September 2024
Summary:
Alnylam Pharmaceuticals quarterly cash flow from investing activities is currently -$30.25 million, with the most recent change of -$64.19 million (-189.13%) on 30 September 2024. Over the past year, it has dropped by -$19.49 million (-181.03%). ALNY quarterly CFI is now -109.64% below its all-time high of $313.89 million, reached on 30 September 2022.ALNY Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFI
-$304.59 M
-$19.49 M-6.83%
30 September 2024
Summary:
Alnylam Pharmaceuticals TTM cash flow from investing activities is currently -$304.59 million, with the most recent change of -$19.49 million (-6.83%) on 30 September 2024. Over the past year, it has dropped by -$68.98 million (-29.28%). ALNY TTM CFI is now -159.67% below its all-time high of $510.41 million, reached on 31 March 2019.ALNY TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ALNY Cash From Investing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -298.6% | -181.0% | -29.3% |
| 3 y3 years | +22.8% | +65.7% | -821.5% |
| 5 y5 years | -223.2% | -200.2% | -684.2% |
ALNY Cash From Investing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -298.6% | +22.8% | -109.6% | +92.7% | -226.6% | +39.8% |
| 5 y | 5 years | -223.2% | +22.8% | -109.6% | +93.1% | -226.6% | +45.5% |
| alltime | all time | -223.2% | +38.7% | -109.6% | +93.1% | -159.7% | +45.5% |
Alnylam Pharmaceuticals Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$30.25 M(-189.1%) | -$304.59 M(+6.8%) |
| June 2024 | - | $33.94 M(-150.2%) | -$285.10 M(-13.0%) |
| Mar 2024 | - | -$67.62 M(-71.9%) | -$327.75 M(-2.6%) |
| Dec 2023 | -$336.35 M(-298.6%) | -$240.66 M(+2135.7%) | -$336.35 M(+42.8%) |
| Sept 2023 | - | -$10.76 M(+23.5%) | -$235.60 M(-364.6%) |
| June 2023 | - | -$8.71 M(-88.6%) | $89.05 M(-63.0%) |
| Mar 2023 | - | -$76.22 M(-45.5%) | $240.56 M(+42.0%) |
| Dec 2022 | $169.35 M(-162.0%) | -$139.91 M(-144.6%) | $169.35 M(-262.6%) |
| Sept 2022 | - | $313.89 M(+119.8%) | -$104.14 M(-79.4%) |
| June 2022 | - | $142.79 M(-196.9%) | -$506.30 M(+2.9%) |
| Mar 2022 | - | -$147.42 M(-64.3%) | -$492.07 M(+80.0%) |
| Dec 2021 | -$273.30 M(-37.2%) | -$413.40 M(+368.3%) | -$273.30 M(-747.4%) |
| Sept 2021 | - | -$88.27 M(-156.2%) | $42.22 M(-64.9%) |
| June 2021 | - | $157.02 M(+120.1%) | $120.40 M(-125.2%) |
| Mar 2021 | - | $71.35 M(-172.9%) | -$477.85 M(+9.7%) |
| Dec 2020 | -$435.52 M(+4.3%) | -$97.89 M(+870.3%) | -$435.52 M(-22.0%) |
| Sept 2020 | - | -$10.09 M(-97.7%) | -$558.48 M(+0.0%) |
| June 2020 | - | -$441.23 M(-488.1%) | -$558.47 M(+37.3%) |
| Mar 2020 | - | $113.69 M(-151.5%) | -$406.64 M(-2.6%) |
| Dec 2019 | -$417.68 M(-253.0%) | -$220.85 M(+2091.6%) | -$417.68 M(-901.1%) |
| Sept 2019 | - | -$10.08 M(-96.5%) | $52.14 M(-67.1%) |
| June 2019 | - | -$289.40 M(-381.9%) | $158.39 M(-69.0%) |
| Mar 2019 | - | $102.65 M(-58.8%) | $510.41 M(+87.0%) |
| Dec 2018 | $272.94 M(-194.0%) | $248.96 M(+158.9%) | $272.94 M(-299.8%) |
| Sept 2018 | - | $96.17 M(+53.6%) | -$136.61 M(-63.1%) |
| June 2018 | - | $62.62 M(-146.4%) | -$369.96 M(-26.0%) |
| Mar 2018 | - | -$134.81 M(-16.0%) | -$500.25 M(+72.3%) |
| Dec 2017 | -$290.36 M(-303.6%) | -$160.59 M(+17.1%) | -$290.36 M(+888.2%) |
| Sept 2017 | - | -$137.18 M(+102.7%) | -$29.38 M(-138.5%) |
| June 2017 | - | -$67.67 M(-190.1%) | $76.39 M(-23.4%) |
| Mar 2017 | - | $75.08 M(-25.2%) | $99.73 M(-30.1%) |
| Dec 2016 | $142.59 M(-144.4%) | $100.39 M(-419.7%) | $142.59 M(+18.4%) |
| Sept 2016 | - | -$31.41 M(-29.2%) | $120.47 M(-39.9%) |
| June 2016 | - | -$44.34 M(-137.6%) | $200.55 M(+45.4%) |
| Mar 2016 | - | $117.94 M(+50.7%) | $137.95 M(-142.9%) |
| Dec 2015 | -$321.32 M(-41.5%) | $78.27 M(+60.8%) | -$321.32 M(-15.0%) |
| Sept 2015 | - | $48.67 M(-145.5%) | -$378.16 M(-2.8%) |
| June 2015 | - | -$106.94 M(-68.7%) | -$388.92 M(-23.8%) |
| Mar 2015 | - | -$341.33 M(-1692.4%) | -$510.36 M(-7.0%) |
| Dec 2014 | -$548.81 M | $21.43 M(-43.5%) | -$548.81 M(+6.7%) |
| Sept 2014 | - | $37.91 M(-116.6%) | -$514.20 M(-7.3%) |
| June 2014 | - | -$228.38 M(-39.9%) | -$554.61 M(+46.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2014 | - | -$379.78 M(-777.6%) | -$379.44 M(+190.8%) |
| Dec 2013 | -$130.50 M(-3968.0%) | $56.05 M(-2338.3%) | -$130.50 M(-8.8%) |
| Sept 2013 | - | -$2.50 M(-95.3%) | -$143.04 M(+16.6%) |
| June 2013 | - | -$53.21 M(-59.3%) | -$122.68 M(+98.3%) |
| Mar 2013 | - | -$130.84 M(-400.7%) | -$61.87 M(-1933.8%) |
| Dec 2012 | $3.37 M(-95.9%) | $43.51 M(+143.7%) | $3.37 M(-117.4%) |
| Sept 2012 | - | $17.85 M(+134.9%) | -$19.36 M(+1922.5%) |
| June 2012 | - | $7.60 M(-111.6%) | -$957.00 K(-83.8%) |
| Mar 2012 | - | -$65.59 M(-415.6%) | -$5.92 M(-107.2%) |
| Dec 2011 | $81.96 M(+359.5%) | $20.78 M(-42.7%) | $81.96 M(-24.6%) |
| Sept 2011 | - | $36.25 M(+1274.7%) | $108.75 M(+40.9%) |
| June 2011 | - | $2.64 M(-88.2%) | $77.19 M(+62.2%) |
| Mar 2011 | - | $22.29 M(-53.2%) | $47.59 M(+166.8%) |
| Dec 2010 | $17.84 M(+23.6%) | $47.58 M(+915.8%) | $17.84 M(-31.1%) |
| Sept 2010 | - | $4.68 M(-117.4%) | $25.88 M(-395.4%) |
| June 2010 | - | -$26.96 M(+261.3%) | -$8.76 M(-67.7%) |
| Mar 2010 | - | -$7.46 M(-113.4%) | -$27.15 M(-288.1%) |
| Dec 2009 | $14.43 M(-19.5%) | $55.62 M(-285.7%) | $14.43 M(-138.2%) |
| Sept 2009 | - | -$29.95 M(-34.0%) | -$37.79 M(-14.7%) |
| June 2009 | - | -$45.36 M(-232.9%) | -$44.28 M(-8.1%) |
| Mar 2009 | - | $34.13 M(+904.0%) | -$48.18 M(-368.6%) |
| Dec 2008 | $17.94 M(-106.5%) | $3.40 M(-109.3%) | $17.94 M(-124.5%) |
| Sept 2008 | - | -$36.45 M(-26.0%) | -$73.15 M(-63.9%) |
| June 2008 | - | -$49.26 M(-149.1%) | -$202.59 M(+59.1%) |
| Mar 2008 | - | $100.24 M(-214.3%) | -$127.33 M(-54.1%) |
| Dec 2007 | -$277.43 M(+823.3%) | -$87.69 M(-47.1%) | -$277.43 M(+42.6%) |
| Sept 2007 | - | -$165.89 M(-737.9%) | -$194.58 M(+632.4%) |
| June 2007 | - | $26.00 M(-152.2%) | -$26.57 M(-60.5%) |
| Mar 2007 | - | -$49.85 M(+930.2%) | -$67.19 M(+123.6%) |
| Dec 2006 | -$30.05 M(-25.7%) | -$4.84 M(-328.4%) | -$30.05 M(-58.5%) |
| Sept 2006 | - | $2.12 M(-114.5%) | -$72.42 M(+3.4%) |
| June 2006 | - | -$14.62 M(+15.0%) | -$70.07 M(+34.2%) |
| Mar 2006 | - | -$12.71 M(-73.1%) | -$52.22 M(+29.2%) |
| Dec 2005 | -$40.42 M(+16.8%) | -$47.21 M(-1155.3%) | -$40.42 M(-624.0%) |
| Sept 2005 | - | $4.47 M(+38.5%) | $7.71 M(-166.0%) |
| June 2005 | - | $3.23 M(-455.7%) | -$11.70 M(-65.0%) |
| Mar 2005 | - | -$908.00 K(-198.9%) | -$33.43 M(-3.4%) |
| Dec 2004 | -$34.59 M(+967.7%) | $918.00 K(-106.1%) | -$34.59 M(-2.6%) |
| Sept 2004 | - | -$14.94 M(-19.3%) | -$35.51 M(+72.6%) |
| June 2004 | - | -$18.51 M(+793.1%) | -$20.58 M(+893.1%) |
| Mar 2004 | - | -$2.07 M | -$2.07 M |
| Dec 2003 | -$3.24 M(+476.5%) | - | - |
| Dec 2002 | -$562.00 K | - | - |
FAQ
- What is Alnylam Pharmaceuticals annual cash flow from investing activities?
- What is the all time high annual CFI for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals annual CFI year-on-year change?
- What is Alnylam Pharmaceuticals quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals quarterly CFI year-on-year change?
- What is Alnylam Pharmaceuticals TTM cash flow from investing activities?
- What is the all time high TTM CFI for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals TTM CFI year-on-year change?
What is Alnylam Pharmaceuticals annual cash flow from investing activities?
The current annual CFI of ALNY is -$336.35 M
What is the all time high annual CFI for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high annual cash flow from investing activities is $272.94 M
What is Alnylam Pharmaceuticals annual CFI year-on-year change?
Over the past year, ALNY annual cash flow from investing activities has changed by -$505.70 M (-298.61%)
What is Alnylam Pharmaceuticals quarterly cash flow from investing activities?
The current quarterly CFI of ALNY is -$30.25 M
What is the all time high quarterly CFI for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high quarterly cash flow from investing activities is $313.89 M
What is Alnylam Pharmaceuticals quarterly CFI year-on-year change?
Over the past year, ALNY quarterly cash flow from investing activities has changed by -$19.49 M (-181.03%)
What is Alnylam Pharmaceuticals TTM cash flow from investing activities?
The current TTM CFI of ALNY is -$304.59 M
What is the all time high TTM CFI for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high TTM cash flow from investing activities is $510.41 M
What is Alnylam Pharmaceuticals TTM CFI year-on-year change?
Over the past year, ALNY TTM cash flow from investing activities has changed by -$68.98 M (-29.28%)